Takala, Jaana http://orcid.org/0000-0001-8753-3341
Vähätalo, Iida
Tuomisto, Leena E.
Niemelä, Onni
Ilmarinen, Pinja
Kankaanranta, Hannu
Funding for this research was provided by:
The Allergy Research Foundation, Finland
Tampereen Tuberkuloosisäätiö
Hengityssairauksien Tutkimussäätiö
The Pihkahovi Foundation
Suomen Tuberkuloosin Vastustamisyhdistyksen Säätiö
Ida Montinin Säätiö
Pirkanmaan Rahasto
The Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital, Finland
Medical Research Fund of Seinäjoki Central Hospital, Finland
Article History
Received: 23 September 2021
Accepted: 2 February 2022
First Online: 15 February 2022
Declarations
:
: Institutional permissions (TU1114 and LET) were obtained and all enrolled patients in SAAS-study cohort signed informed consent to the study protocol approved by the Ethics committee of Tampere University Hospital, Tampere, Finland (R12122). Permission for use and the data concerning dispensed medication for was granted by the Finnish Social Insurance Institution.
: Not applicable.
: None of the authors declares any competing interests concerning this article. Dr. Takala reports personal fees from Novartis, personal fees and non-financial support from NovoNordisk and non-financial support from GSK, outside the submitted work. Dr. Vähätalo reports personal fees from AstraZeneca, outside the submitted work. Dr. Tuomisto reports personal fees from AstraZeneca, Boehringer-Ingelheim, and GlaxoSmithKline, outside the submitted work. Dr. Niemelä has nothing to disclose. Dr. Ilmarinen is an employee of GlaxoSmithKline. Dr. Ilmarinen reports personal fees from GlaxoSmithKline, Novartis, AstraZeneca and Mundipharma, outside the submitted work. Dr. Kankaanranta reports personal fees and non-financial support from AstraZeneca, Boehringer-Ingelheim, and Orion Pharma, personal fees from Chiesi, Novartis, MSD, Mundipharma, SanofiGenzyme, and GlaxoSmithKline, outside the submitted work.